STEREOTAXIS INC (STXS)

US85916J4094 - Common Stock

2.3124  +0.02 (+0.98%)

Fundamental Rating

2

Taking everything into account, STXS scores 2 out of 10 in our fundamental rating. STXS was compared to 187 industry peers in the Health Care Equipment & Supplies industry. While STXS seems to be doing ok healthwise, there are quite some concerns on its profitability. STXS is quite expensive at the moment. It does show a decent growth rate.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

STXS had negative earnings in the past year.
In the past year STXS has reported a negative cash flow from operations.
STXS had negative earnings in each of the past 5 years.
In the past 5 years STXS always reported negative operating cash flow.

1.2 Ratios

STXS has a Return On Assets of -44.95%. This is in the lower half of the industry: STXS underperforms 63.10% of its industry peers.
Looking at the Return On Equity, with a value of -141.11%, STXS is doing worse than 71.66% of the companies in the same industry.
Industry RankSector Rank
ROA -44.95%
ROE -141.11%
ROIC N/A
ROA(3y)-36.39%
ROA(5y)-27.49%
ROE(3y)-64.24%
ROE(5y)-46.75%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

STXS has a Gross Margin (56.14%) which is in line with its industry peers.
STXS's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for STXS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 56.14%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.98%
GM growth 5Y-7.17%

More info and screens

4

2. Health

2.1 Basic Checks

STXS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for STXS has been increased compared to 1 year ago.
The number of shares outstanding for STXS has been increased compared to 5 years ago.
There is no outstanding debt for STXS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -12.65, we must say that STXS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -12.65, STXS is not doing good in the industry: 82.35% of the companies in the same industry are doing better.
There is no outstanding debt for STXS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.65
ROIC/WACCN/A
WACC9.26%

2.3 Liquidity

STXS has a Current Ratio of 1.39. This is a normal value and indicates that STXS is financially healthy and should not expect problems in meeting its short term obligations.
STXS's Current ratio of 1.39 is on the low side compared to the rest of the industry. STXS is outperformed by 81.28% of its industry peers.
A Quick Ratio of 0.96 indicates that STXS may have some problems paying its short term obligations.
The Quick ratio of STXS (0.96) is worse than 80.75% of its industry peers.
Industry RankSector Rank
Current Ratio 1.39
Quick Ratio 0.96

More info and screens

4

3. Growth

3.1 Past

The earnings per share for STXS have decreased by -3.70% in the last year.
STXS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -14.80%.
The Revenue has been decreasing by -1.82% on average over the past years.
EPS 1Y (TTM)-3.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
Revenue 1Y (TTM)-14.8%
Revenue growth 3Y0.18%
Revenue growth 5Y-1.82%
Sales Q2Q%17.91%

3.2 Future

Based on estimates for the next years, STXS will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.94% on average per year.
The Revenue is expected to grow by 30.97% on average over the next years. This is a very strong growth
EPS Next Y10.75%
EPS Next 2Y15.16%
EPS Next 3Y16.94%
EPS Next 5YN/A
Revenue Next Year-11.2%
Revenue Next 2Y17.56%
Revenue Next 3Y30.97%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for STXS. In the last year negative earnings were reported.
Also next year STXS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as STXS's earnings are expected to grow with 16.94% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.16%
EPS Next 3Y16.94%

More info and screens

0

5. Dividend

5.1 Amount

STXS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

STEREOTAXIS INC

NYSEARCA:STXS (12/30/2024, 11:42:45 AM)

2.3124

+0.02 (+0.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-11 2024-11-11/amc
Earnings (Next)N/A N/A
Inst Owners48.29%
Inst Owner Change0.73%
Ins Owners1.99%
Ins Owner Change5.64%
Market Cap195.93M
Analysts82
Price Target4.59 (98.5%)
Short Float %3.56%
Short Ratio7.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-40.06%
Min EPS beat(2)-49.39%
Max EPS beat(2)-30.72%
EPS beat(4)1
Avg EPS beat(4)-19.74%
Min EPS beat(4)-49.39%
Max EPS beat(4)5.12%
EPS beat(8)3
Avg EPS beat(8)-11.79%
EPS beat(12)5
Avg EPS beat(12)-9.69%
EPS beat(16)7
Avg EPS beat(16)-10.86%
Revenue beat(2)1
Avg Revenue beat(2)2.72%
Min Revenue beat(2)-21.54%
Max Revenue beat(2)26.98%
Revenue beat(4)1
Avg Revenue beat(4)-10.02%
Min Revenue beat(4)-41.88%
Max Revenue beat(4)26.98%
Revenue beat(8)2
Avg Revenue beat(8)-6.41%
Revenue beat(12)4
Avg Revenue beat(12)-5.55%
Revenue beat(16)7
Avg Revenue beat(16)-1.91%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-23.81%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-29.18%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.79
P/FCF N/A
P/OCF N/A
P/B 12.08
P/tB 54.93
EV/EBITDA N/A
EPS(TTM)-0.28
EYN/A
EPS(NY)-0.19
Fwd EYN/A
FCF(TTM)-0.14
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS0.3
BVpS0.19
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.95%
ROE -141.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 56.14%
FCFM N/A
ROA(3y)-36.39%
ROA(5y)-27.49%
ROE(3y)-64.24%
ROE(5y)-46.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.98%
GM growth 5Y-7.17%
F-Score4
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.78%
Cap/Sales 0.11%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.39
Quick Ratio 0.96
Altman-Z -12.65
F-Score4
WACC9.26%
ROIC/WACCN/A
Cap/Depr(3y)629.24%
Cap/Depr(5y)393.32%
Cap/Sales(3y)4.61%
Cap/Sales(5y)2.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
EPS Next Y10.75%
EPS Next 2Y15.16%
EPS Next 3Y16.94%
EPS Next 5YN/A
Revenue 1Y (TTM)-14.8%
Revenue growth 3Y0.18%
Revenue growth 5Y-1.82%
Sales Q2Q%17.91%
Revenue Next Year-11.2%
Revenue Next 2Y17.56%
Revenue Next 3Y30.97%
Revenue Next 5YN/A
EBIT growth 1Y-6.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year50.63%
EBIT Next 3Y16.81%
EBIT Next 5YN/A
FCF growth 1Y-18.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-54.07%
OCF growth 3YN/A
OCF growth 5YN/A